FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617594540> ?p ?o ?g. }

• W2617594540 endingPage "910" @default.
• W2617594540 startingPage "883" @default.
• W2617594540 abstract "In this Commission, we argue that a combination of poor quality science, unclear funding models, unrealistic hopes, and unscrupulous private clinics threatens regenerative medicine's social licence to operate. If regenerative medicine is to shift from mostly small-scale bespoke experimental interventions into routine clinical practice, substantial rethinking of the social contract that supports such research and clinical practice in the public arena will be required.For decades, stem cell therapy was predominantly limited to bone marrow transplantation for haematological diseases and epidermis transplantation for large burns. Tissue engineering and gene therapy faced huge challenges on their way to clinical translation—a situation that began to change only at the end of the 1990s. The past 10 years have seen an exponential growth in experimental therapies, broadly defined as regenerative medicine, entering the clinical arena. Results vary from unequivocal clinical efficacy for previously incurable and devastating diseases to (more frequently) a modest or null effect. The reasons for these widely different outcomes are starting to emerge.At this stage in their evolution, these experimental therapies (which include, but are not limited to, cell and gene therapy, tissue engineering, and new generation drugs) are necessarily financially expensive. Rigorous and costly clinical-grade procedures have to be followed in the development of medicinal products (involving cells, genetically manipulated cells, viral vectors, or biomaterials with or without cells), often produced in a very limited run. The cost of developing sufficiently high-quality trials means that only wealthier countries are able to fund them. Although public investments in this field are massive internationally, they do not carry guaranteed commercial returns. Compared with conventional drug development, such products follow a highly uncertain route to market. Furthermore, new therapies expose patients to risks, some of which are difficult to predict even with inbuilt safeguards.Despite the relatively small number of clinical successes, optimism and excitement about the potential effect or implications of this field remain great. This enthusiasm has led to gaps between people's expectations that new therapies should be available, often inflated by media reports, and the realities of translating regenerative technologies into clinical practice. The same environment is also permissive of one-off compassionate applications and poorly regulated trials. Indeed, the number of poorly regulated clinics has grown; clinics that appeal to desperate patients and their families, who, in the absence of reliable clinical knowledge from trials, cannot be adequately informed to assess the risks and benefits.These ethical and governance issues pose a challenge to scientists in engaging with the public, the press, and decision-making bodies in different national health systems. Political agendas might not coincide with the public good. In poorly regulated states, the authorisation of a novel therapy might be politically attractive, even when efficacy is unconfirmed, and the cost to taxpayers means other patients are deprived of established and effective therapies. These challenges are difficult to address and solve. We recommend a solution that lies in a coordinated strategy with four pillars: better science, better funding models, better governance, and better public and patient engagement." @default.
• W2617594540 created "2017-06-05" @default.
• W2617594540 creator A5003496082 @default.
• W2617594540 creator A5013464477 @default.
• W2617594540 creator A5015856478 @default.
• W2617594540 creator A5018463374 @default.
• W2617594540 creator A5018585485 @default.
• W2617594540 creator A5019123412 @default.
• W2617594540 creator A5021618906 @default.
• W2617594540 creator A5026128902 @default.
• W2617594540 creator A5030547237 @default.
• W2617594540 creator A5030615643 @default.
• W2617594540 creator A5033139713 @default.
• W2617594540 creator A5035337446 @default.
• W2617594540 creator A5036586986 @default.
• W2617594540 creator A5048785509 @default.
• W2617594540 creator A5052096851 @default.
• W2617594540 creator A5063479446 @default.
• W2617594540 creator A5076463795 @default.
• W2617594540 creator A5082849793 @default.
• W2617594540 creator A5088838250 @default.
• W2617594540 date "2018-03-01" @default.
• W2617594540 modified "2023-10-13" @default.
• W2617594540 title "Lancet Commission: Stem cells and regenerative medicine" @default.
• W2617594540 cites W1436283894 @default.
• W2617594540 cites W1538808416 @default.
• W2617594540 cites W1600024584 @default.
• W2617594540 cites W1760710699 @default.
• W2617594540 cites W1812829745 @default.
• W2617594540 cites W1920407368 @default.
• W2617594540 cites W1949952721 @default.
• W2617594540 cites W1950973286 @default.
• W2617594540 cites W1965378998 @default.
• W2617594540 cites W1968382194 @default.
• W2617594540 cites W1968405249 @default.
• W2617594540 cites W1969271703 @default.
• W2617594540 cites W1969345121 @default.
• W2617594540 cites W1969607632 @default.
• W2617594540 cites W1972463994 @default.
• W2617594540 cites W1974946414 @default.
• W2617594540 cites W1976594465 @default.
• W2617594540 cites W1977486219 @default.
• W2617594540 cites W1980142637 @default.
• W2617594540 cites W1983711895 @default.
• W2617594540 cites W1984672300 @default.
• W2617594540 cites W1986557831 @default.
• W2617594540 cites W1986947784 @default.
• W2617594540 cites W1992525863 @default.
• W2617594540 cites W1992985034 @default.
• W2617594540 cites W1993388098 @default.
• W2617594540 cites W1993839684 @default.
• W2617594540 cites W1994064996 @default.
• W2617594540 cites W1997610423 @default.
• W2617594540 cites W2001962483 @default.
• W2617594540 cites W2004149383 @default.
• W2617594540 cites W2005356516 @default.
• W2617594540 cites W2007289264 @default.
• W2617594540 cites W2007398635 @default.
• W2617594540 cites W2007879649 @default.
• W2617594540 cites W2010474967 @default.
• W2617594540 cites W2010757394 @default.
• W2617594540 cites W2013443686 @default.
• W2617594540 cites W2016715437 @default.
• W2617594540 cites W2018258390 @default.
• W2617594540 cites W2018274135 @default.
• W2617594540 cites W2023339971 @default.
• W2617594540 cites W2023615381 @default.
• W2617594540 cites W2025569286 @default.
• W2617594540 cites W2026204738 @default.
• W2617594540 cites W2028266585 @default.
• W2617594540 cites W2030646994 @default.
• W2617594540 cites W2032678451 @default.
• W2617594540 cites W2041160650 @default.
• W2617594540 cites W2042278117 @default.
• W2617594540 cites W2043611538 @default.
• W2617594540 cites W2044542313 @default.
• W2617594540 cites W2045899482 @default.
• W2617594540 cites W2048644480 @default.
• W2617594540 cites W2050419057 @default.
• W2617594540 cites W2050480410 @default.
• W2617594540 cites W2052095342 @default.
• W2617594540 cites W2052185355 @default.
• W2617594540 cites W2054198878 @default.
• W2617594540 cites W2056320636 @default.
• W2617594540 cites W2057879405 @default.
• W2617594540 cites W2059030377 @default.
• W2617594540 cites W2060699946 @default.
• W2617594540 cites W2063048290 @default.
• W2617594540 cites W2063590777 @default.
• W2617594540 cites W2064906046 @default.
• W2617594540 cites W2069830811 @default.
• W2617594540 cites W2071949537 @default.
• W2617594540 cites W2073400818 @default.
• W2617594540 cites W2075580305 @default.
• W2617594540 cites W2077547828 @default.
• W2617594540 cites W2078616377 @default.
• W2617594540 cites W2079579689 @default.
• W2617594540 cites W2081836669 @default.

• next